Skip to main content

Table 2 Treatment effect and complication in study groups

From: Non-invasive duo positive airway pressure ventilation versus nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome: a randomized controlled trial

Characteristic NDUOPAP NCPAP P value
Failure in first 72 h, n (%) 3(4.1%) 6(8.1%) 0.494
Duration of Noninvasive Respiratory support (hr)
(mean± SD)
39.18±18.14 50.12±23.83 0.004
Duration of oxygen therapy (hr)
(mean± SD)
75.48±26.06 107.45±156.06 0.034
Duration of hospitalization (hr)
Mean ± SD)
495.88±310.11 668.08±360.46 0.002
Pneumothorax, n median (IQR) 0(0) 2(2.7) 0.497
IVH, n (%)
Grade I & II
3(4.1) 5(6.8) 0.719
PDA mild, n (%) 4(5.4%) 5(6.8%) 1
PDA moderate, n (%) 4(5.4) 3(4.1) 1
BPD, n (%) 0(0) 1(1.4) 0.319
Apnea, n (%) 1(1.4%) 4(5.4%) 0.366
Deaths, n (%) 2(2.7%) 5(6.8%) 0.442
Surfactant
First dose, n (%)
31(41.9%) 39(52.7%) 0.042
Surfactant
Secondary dose, n (%)
13(17.6%) 20(27%) 0.042
Surfactant
3 dose, n (%)
2(2.7%) 1(1.4%) 0.042
  1. h hour, PDA Patent Ductus Arteriosus, n number, BPD Bronchopulmonary dysplasia, IQR Inter Quartile Range, IVH Intra Ventricular hemorrhage